You are invited to attend a free web-cast event SATURDAY, APRIL 22, 2017

RARE LUNG DISEASES PATIENT EDUCATION DAY ON CYSTIC FIBROSIS, CHILDREN’S INTERSTITIAL LUNG DISEASE AND PRIMARY CILIARY DYSKINESIA

REGISTER NOW AT:
https://attendee.gotowebinar.com/register/6993341835513746691

This event is co-sponsored by the American Thoracic Society, the Cystic Fibrosis Foundation, the Children’s Interstitial Lung Disease Foundation and the Primary Continue reading You are invited to attend a free web-cast event SATURDAY, APRIL 22, 2017

Gastroparesis and Cystic Fibrosis – By Meranda Sue Honaker

By Meranda Sue Honaker

Gastroparesis (delayed gastric emptying) is a common complication for many with CF; however, the condition is exceptionally hard to treat due to lack of promotility agents in the United States. In my early 20’s I began to experience Continue reading Gastroparesis and Cystic Fibrosis – By Meranda Sue Honaker

OWN IT: Five Years with the G-Tube

This May marks five years since I had my feeding tube placed, or to put it another way, my G-tube has been with my for 1/5 of my life.

It’s a strange thought. For years I rejected the idea of having a feeding tube – Continue reading OWN IT: Five Years with the G-Tube

UDCA Supplementation Enhances Lipid Digestion and Absorption in Pancreatic Insufficient Patients with Cystic Fibrosis

http://www.hcplive.com/

Results from a trial involving 23 cystic fibrosis patients with pancreatic insufficiency and mild liver involvement indicate that supplementation with ursodeoxycholic acid can increase the digestion and absorption of fat. Continue reading UDCA Supplementation Enhances Lipid Digestion and Absorption in Pancreatic Insufficient Patients with Cystic Fibrosis

Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial

Anthera Pharmaceuticals, Inc., a biopharmaceutical company that specializes in research and development of novel treatments for serious and fatal diseases such as lupus, lupus with nephrotic affectation, and exocrine pancreatic insufficiency (EPI) secondary to cystic fibrosis Continue reading Anthera, Patheon to Co-Manufacture Sollpura for CF Phase 3 Trial

Pitt-led study suggests cystic fibrosis is 2 diseases, 1 doesn’t affect lungs

Cystic fibrosis (CF) could be considered two diseases, one that affects multiple organs including the lungs, and one that doesn’t affect the lungs at all, according to a multicenter team led by researchers at the University of Pittsburgh School of Medicine. The research, published online today in PLOS Continue reading Pitt-led study suggests cystic fibrosis is 2 diseases, 1 doesn’t affect lungs

Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption

After the Food and Drug Administration (FDA) issued rules requiring approval of pancreatic enzyme products (PEPs) in 2004, the cost and availability of the products added another hardship to the lives of cystic fibrosis patients, some of whom use PEPs to prevent uncomfortable and Continue reading Pancreatic Enzyme Products May Benefit Cystic Fibrosis Patients with Malabsorption

2013 CFRI Retreat Review

CFRI Retreat – 2013 Version

            The 2013 version(Party of a Lifetime) of CFRI Retreat was another amazing success! With Jessica Martens and her committee leading the way, the retreat was full of fun, education, exercise, laughter, and tears. CF participants aged in range from 17-56, with two people in their 50s and several now in their 40s and late 30s. YES, we are getting older and wiser! Continue reading 2013 CFRI Retreat Review

Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

CARY, N.C., July 29, 2013 – Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today it is now actively marketing PERTZYE® (pancrelipase) in the U.S. for the treatment of Exocrine Pancreatic Insufficiency (EPI) due to cystic fibrosis. PERTZYE is the only U.S. Food and Drug Administration (FDA) approved pancreatic enzyme replacement therapy (PERT) containing Continue reading Cornerstone Therapeutics Initiates PERTZYE® (pancrelipase) Sales and Marketing Efforts for the Treatment of Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

Weekend Traffic Jam: My CF’n Vacation–Guest Blog by Maria Fioccola

Last minute overnight vacations are meant to be fun and relaxing, or so I thought. Last Thursday my aunt texted me that she was going to see my grandma, who lives roughly 500 miles away. I obviously knew this was more than an overnight adventure when she asked if I wanted to join. I felt I needed to get away for a couple days because I felt I was being Continue reading Weekend Traffic Jam: My CF’n Vacation–Guest Blog by Maria Fioccola